Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07526350 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

MTS109 in Patients With Refractory Autoimmune Diseases

StatusRecruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study description expanded, about 4 wordsv3
  2. Eligibility criteria shortened, about 27 words
    • Secondary endpoints revised (13)
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is the first-in-human trial of MTS109 (mRNA-LNP). The goal of this clinical trial is to evaluate the safety, tolerability of intravenous injection of MTS109 in moderate to severe autoimmune diseases.
Trial Details
NCT Number NCT07526350
Lead Sponsor Shanghai Changzheng Hospital
Collaborators: Metis Techbio
Conditions
(from sponsor)		 Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Systemic Sclerosis (SSc), ANCA-Associated Vasculitis (AAV), Sjogren's Syndrome (SS)
Related terms Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Lupus Erythematosus, Systemic, Myositis, Scleroderma, Systemic, Sjogren's Syndrome
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov